Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 2500.000000 0 FOR 2500.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers. SECTION 14A SAY-ON-PAY VOTES 2500.000000 0 ONE YEAR 2500.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To cast a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 34500.000000 0 FOR 34500.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every: SECTION 14A SAY-ON-PAY VOTES 34500.000000 0 ONE YEAR 34500.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Approving, on an advisory basis, the Company's executive compensation; SECTION 14A SAY-ON-PAY VOTES 29350.000000 0 FOR 29350.000000 FOR Viatris Inc. 92556V106 US92556V1061 12/06/2024 Approval of, on a non-binding advisory basis, the 2023 compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES 19500.000000 0 AGAINST 19500.000000 AGAINST Johnson & Johnson 478160104 US4781601046 04/24/2025 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES 17800.000000 0 FOR 17800.000000 FOR Pfizer Inc. 717081103 US7170811035 04/24/2025 2025 advisory approval of executive compensation SECTION 14A SAY-ON-PAY VOTES 59650.000000 0 AGAINST 59650.000000 AGAINST Abbott Laboratories 002824100 US0028241000 04/25/2025 Say on Pay - An Advisory Vote on the Approval of Executive Compensation SECTION 14A SAY-ON-PAY VOTES 24398.000000 0 FOR 24398.000000 FOR Moderna, Inc. 60770K107 US60770K1079 04/30/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 4350.000000 0 AGAINST 4350.000000 AGAINST Boston Scientific Corporation 101137107 US1011371077 05/01/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 26926.000000 0 FOR 26926.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 To approve, by advisory vote, the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 4750.000000 0 FOR 4750.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/05/2025 Approval, on an advisory basis, of the compensation paid to the company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 9716.000000 0 FOR 9716.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Advisory Vote to Approve the Compensation of our Named Executive Officers SECTION 14A SAY-ON-PAY VOTES 19500.000000 0 FOR 19500.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To approve on an advisory basis the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 10575.000000 0 FOR 10575.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 27780.000000 0 FOR 27780.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. SECTION 14A SAY-ON-PAY VOTES 4050.000000 0 FOR 4050.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2024. SECTION 14A SAY-ON-PAY VOTES 15000.000000 0 FOR 15000.000000 FOR Edwards Lifesciences Corporation 28176E108 US28176E1082 05/08/2025 Advisory Vote to Approve Named Executive Officer Compensation SECTION 14A SAY-ON-PAY VOTES 6000.000000 0 FOR 6000.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Advisory Vote to Approve Named Executive Officer Compensation. SECTION 14A SAY-ON-PAY VOTES 6100.000000 0 FOR 6100.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Say on Pay - An advisory vote on the approval of executive compensation SECTION 14A SAY-ON-PAY VOTES 16800.000000 0 FOR 16800.000000 FOR Royalty Pharma Plc G7709Q104 GB00BMVP7Y09 05/12/2025 A non-binding advisory vote to approve executive compensation that may become payable in connection with the transaction contemplated by the Membership Interest Purchase Agreement. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR Royalty Pharma Plc G7709Q104 GB00BMVP7Y09 05/12/2025 A non-binding advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 15695.000000 0 FOR 15695.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/14/2025 Advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 1500.000000 0 FOR 1500.000000 FOR SpringWorks Therapeutics, Inc. 85205L107 US85205L1070 05/14/2025 Non-binding advisory vote on executive compensation SECTION 14A SAY-ON-PAY VOTES 23415.000000 0 FOR 23415.000000 FOR Vera Therapeutics, Inc. 92337R101 US92337R1014 05/14/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 26620.000000 0 FOR 26620.000000 FOR Vera Therapeutics, Inc. 92337R101 US92337R1014 05/14/2025 To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 26620.000000 0 ONE YEAR 26620.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 3670.000000 0 FOR 3670.000000 FOR Insmed Incorporated 457669307 US4576693075 05/15/2025 An advisory vote on the 2024 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 11971.000000 0 FOR 11971.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2025 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES 415.000000 0 FOR 415.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 20800.000000 0 FOR 20800.000000 FOR BeiGene Ltd. 07725L102 US07725L1026 05/21/2025 THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, be and is hereby approved. SECTION 14A SAY-ON-PAY VOTES 2285.000000 0 AGAINST 2285.000000 AGAINST Illumina, Inc. 452327109 US4523271090 05/21/2025 To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 2882.000000 0 FOR 2882.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 Advisory vote on the compensation paid to the Company's named executive officers; SECTION 14A SAY-ON-PAY VOTES 2300.000000 0 FOR 2300.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 An advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 3250.000000 0 AGAINST 3250.000000 AGAINST Amgen Inc. 031162100 US0311621009 05/23/2025 Advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES 8650.000000 0 FOR 8650.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Non-binding advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 38500.000000 0 FOR 38500.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES 12895.000000 0 AGAINST 12895.000000 AGAINST Cogent Biosciences, Inc. 19240Q201 US19240Q2012 06/04/2025 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 71400.000000 0 FOR 71400.000000 FOR Amicus Therapeutics, Inc. 03152W109 US03152W1099 06/05/2025 Approval, on an advisory basis, the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES 96820.000000 0 FOR 96820.000000 FOR CRISPR Therapeutics AG H17182108 CH0334081137 06/05/2025 Non-binding advisory vote on the compensation paid to the Company's named executive officers under U.S. securities law requirements. SECTION 14A SAY-ON-PAY VOTES 2000.000000 0 AGAINST 2000.000000 AGAINST Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 To make an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 7200.000000 0 FOR 7200.000000 FOR MoonLake Immunotherapeutics 61559X104 KY61559X1045 06/05/2025 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 13687.000000 0 FOR 13687.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/06/2025 To approve, by non-binding advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 820.000000 0 FOR 820.000000 FOR Arcus Biosciences, Inc. 03969F109 US03969F1093 06/10/2025 To approve, on an advisory basis, the compensation of Arcus Biosciences' named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 21000.000000 0 FOR 21000.000000 FOR Clover Health Investments, Corp. 18914F103 US18914F1030 06/10/2025 Non-binding advisory proposal to approve the compensation paid to our named executive officers for 2024. SECTION 14A SAY-ON-PAY VOTES 183000.000000 0 FOR 183000.000000 FOR Incyte Corporation 45337C102 US45337C1027 06/10/2025 Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 4700.000000 0 FOR 4700.000000 FOR RadNet, Inc. 750491102 US7504911022 06/10/2025 An advisory vote to approve the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES 20000.000000 0 FOR 20000.000000 FOR Crinetics Pharmaceuticals, Inc. 22663K107 US22663K1079 06/11/2025 To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; SECTION 14A SAY-ON-PAY VOTES 4400.000000 0 FOR 4400.000000 FOR Trevi Therapeutics, Inc. 89532M101 US89532M1018 06/11/2025 Approval, on an advisory basis, of the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 96099.000000 0 FOR 96099.000000 FOR Trevi Therapeutics, Inc. 89532M101 US89532M1018 06/11/2025 Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 96099.000000 0 ONE YEAR 96099.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Approval, on an advisory basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES 50400.000000 0 FOR 50400.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 Approval, by a non-binding advisory vote, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES 56500.000000 0 FOR 56500.000000 FOR Tarsus Pharmaceuticals, Inc. 87650L103 US87650L1035 06/12/2025 To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES 16420.000000 0 FOR 16420.000000 FOR Tarsus Pharmaceuticals, Inc. 87650L103 US87650L1035 06/12/2025 To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes on the compensation of our named executive officers will be conducted of one, two or three years. SECTION 14A SAY-ON-PAY VOTES 16420.000000 0 ONE YEAR 16420.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 19100.000000 0 AGAINST 19100.000000 AGAINST Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Proposal to approve, on an advisory basis, executive compensation. SECTION 14A SAY-ON-PAY VOTES 2163.000000 0 FOR 2163.000000 FOR Biogen Inc. 09062X103 US09062X1037 06/17/2025 Say on Pay - To hold an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES 2220.000000 0 AGAINST 2220.000000 AGAINST PTC Therapeutics, Inc. 69366J200 US69366J2006 06/17/2025 Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 6650.000000 0 FOR 6650.000000 FOR Blueprint Medicines Corporation 09627Y109 US09627Y1091 06/18/2025 Approval of a non-binding advisory vote on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES 10820.000000 0 FOR 10820.000000 FOR Recursion Pharmaceuticals, Inc. 75629V104 US75629V1044 06/18/2025 Advisory vote to approve executive compensation as disclosed in the 2025 Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 9100.000000 0 FOR 9100.000000 FOR Zai Lab Limited G9887T116 KYG9887T1168 06/18/2025 THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. SECTION 14A SAY-ON-PAY VOTES 198000.000000 0 FOR 198000.000000 FOR Zai Lab Limited 98887Q104 US98887Q1040 06/18/2025 THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. SECTION 14A SAY-ON-PAY VOTES 11200.000000 0 FOR 11200.000000 FOR BridgeBio Pharma, Inc. 10806X102 US10806X1028 06/20/2025 To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 12500.000000 0 AGAINST 12500.000000 AGAINST Madrigal Pharmaceuticals, Inc. 558868105 US5588681057 06/20/2025 Advisory vote to approve executive compensation SECTION 14A SAY-ON-PAY VOTES 570.000000 0 FOR 570.000000 FOR Madrigal Pharmaceuticals, Inc. 558868105 US5588681057 06/20/2025 Advisory vote to approve the frequency of future advisory votes to approve executive compensation SECTION 14A SAY-ON-PAY VOTES 570.000000 0 ONE YEAR 570.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES 31250.000000 0 FOR 31250.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES 31250.000000 0 ONE YEAR 31250.000000 FOR Phreesia, Inc. 71944F106 US71944F1066 06/25/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES 34000.000000 0 FOR 34000.000000 FOR Revolution Medicines, Inc. 76155X100 US76155X1000 06/26/2025 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES 4900.000000 0 FOR 4900.000000 FOR United Therapeutics Corporation 91307C102 US91307C1027 06/26/2025 Advisory resolution to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES 595.000000 0 FOR 595.000000 FOR